Letermovir
- Generic Name
- Letermovir
- Brand Names
- Prevymis
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F4N4O4
- CAS Number
- 917389-32-3
- Unique Ingredient Identifier
- 1H09Y5WO1F
- Background
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status from the FDA. It is cur...
- Indication
Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in adult kidney transplant recipients who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegat...
- Associated Conditions
- Cytomegalovirus (CMV) Infections
- Associated Therapies
- -
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoblastic LymphomaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaMyelodysplastic SyndromeNon-Hodgkin LymphomaHematopoietic and Lymphoid Cell NeoplasmHodgkin LymphomaMyelofibrosis
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT04060277
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT03930615
- Locations
- 🇺🇸
Indiana Blood and Marrow Transplantation ( Site 0175), Indianapolis, Indiana, United States
🇺🇸The University of Texas MD Anderson Cancer Center ( Site 0154), Houston, Texas, United States
🇫🇷Centre Hospitalier Universitaire Dupuytren ( Site 0182), Limoges, Haute-Vienne, France
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Amy C. Sherman, MD
- Target Recruit Count
- 10
- Registration Number
- NCT03728426
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 601
- Registration Number
- NCT03443869
- Locations
- 🇺🇸
University of Chicago ( Site 0251), Chicago, Illinois, United States
🇺🇸Brigham & Women's Hospital ( Site 0244), Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center ( Site 0264), Columbus, Ohio, United States
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 570
- Registration Number
- NCT02137772
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.